Regulatory Submissions and Approvals

From IND Clinical Hold to Approval: Strategies and Timeline Management

Posted on digi By digi

A clinical hold issued by the FDA on an Investigational New Drug (IND) application stops clinical research activities outright until the agency’s concerns are adequately addressed. Holds may be triggered for safety reasons, unclear data, incomplete chemistry documentation, or gaps in nonclinical toxicology. An IND hold halts trial initiation and significantly extends development timelines—delays that impact both strategy and budget.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Regulatory Sandbox and Pilot Programs: Opportunities for Innovation and Expedited Engagement

Posted on digi By digi

Regulatory sandboxes and associated pilot programs are collaborative initiatives launched by health authorities like the FDA to foster innovation in drug development and evidence generation. These frameworks allow sponsors to test novel approaches—such as use of real-world data, digital health technologies, or advanced manufacturing—within a controlled, regulatory-guided setting.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Monitoring Product Quality in the Post‑Market Phase

Posted on digi By digi

After regulatory approval, product quality must remain rigorously controlled throughout the lifecycle. Post‑market quality monitoring helps detect emerging risks—not just manufacturing deviations, but also supply chain variability, stability trends, and compliance shifts. Without structured oversight, quality drift can harm patient safety, trigger regulatory citations, or even lead to product recalls.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals